7. Zelnorm - Top 10 Warnings and Recalls

Drug: Zelnorm

2006 sales: $561 million

Manufacturer: Novartis

Safety concern: Recall; heart risks

Related Articles:
> FDA allows limited Zelnorm use. Report
> Novartis shares slide after Zelnorm gets yanked. Report
> EMEA committee rejects Novartis' Zelnorm. Report

7. Zelnorm - Top 10 Warnings and Recalls
Read more on

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.